Given the annual budget of more than US$146 million for HIV care funded by Mozambique and donors [60], our analysis suggests that POC-CD4 is a feasible option because the increased associated costs represent 2.2% of what is currently spent on the AIDS response in Mozambique. This evidence concerns the gene CD4 and AIDS.